Targeting CSC-Specific Surface Markers

Identifying unique surface markers expressed by cancer stem cells (CSCs) is key to selectively targeting them without affecting normal stem cells. This track focuses on the discovery of CSC-specific markers such as CD44, CD133, and ALDH1. Researchers aim to develop targeted therapies, including monoclonal antibodies and small molecules, that can specifically recognize and eliminate CSCs. By utilizing these markers for drug delivery or immunotherapy, more precise and effective cancer treatments can be designed. The goal is to reduce tumor recurrence and improve treatment efficacy by targeting the CSC population while sparing healthy tissue, offering a promising approach to cancer therapy.

    Related Conference of Targeting CSC-Specific Surface Markers

    November 25-26, 2024

    7th International Conference on Anti-Cancer Drugs & Therapies

    Vancouver, Canada
    November 28-29, 2024

    14th World Congress on Breast Cancer

    Paris, France
    December 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Dubai, UAE
    December 11-12, 2024

    34th Experts Meet On Cancer Research & Therapy

    Paris, France
    December 12-13, 2024

    44th Euro Congress on Cancer Science & Therapy

    Rome, Italy
    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands

    Targeting CSC-Specific Surface Markers Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in